SGS, a bio/pharmaceutical analytical and bioanalytical contract service provider, is now offering clients large molecule bioanalytical services at its laboratory in Wavre, Belgium. The facility has invested in new and dedicated LC/MS-MS instruments and is currently validating internal methods within the laboratory, ensuring that services will be available by the end of this month.
The investment includes the installation of Sciex instruments, and the introduction of supporting Sciex BioBA sample preparation kits. This will allow the laboratory to handle the analysis of a wide range of samples, including peptides, proteins, and complex biological molecules, such as monoclonal antibodies.
Initially, the service will focus on pre-clinical samples, with the aim of rapidly expanding to analytical methods used for clinical studies.
SGS’s Wavre 90,400 square foot laboratory, on the outskirts of Brussels, provides a wide range of services to clients around the world, including method development and validation, analytical chemistry, microbiological testing, potency assays, and cell line characterization.
With 20 laboratories offering contract analytical and bioanalytical services, SGS leverages its wholly owned global network, present in North America, Europe, and Asia, to deliver harmonized solutions to large pharmaceutical and biotechnology firms.
In addition to testing services for the bio/pharmaceutical market, SGS also provides Phase I-IV clinical trial management, and services encompassing data management and statistics, PK/PD modeling and simulation, pharmacovigilance and regulatory consultancy.
In Europe, the integrated SGS laboratory network contains several specialist service centers providing support for the testing requirements associated with small and large molecule development, including characterization of large molecules and bioanalysis.
The inspection, verification, testing, and certification company is recognized as the global benchmark for quality and integrity. With more than 90,000 employees, SGS operates a network of over 2,000 offices and laboratories around the world.
(Source: SGS S.A.)
Filed Under: Drug Discovery
